Amag Pharmaceuticals, Inc.

Waltham, MA

UEI
LK7MJ8XFA3W1
CAGE
5C9A6
Primary NAICS
325412 Pharmaceutical Preparation Manufacturing
SAM.gov registration
Expired

Company facts

Self-certified in SAM.gov
  • Foreign Owned
  • For Profit Organization
  • Manufacturer of Goods
Entity structure
Corporate Entity (Not Tax Exempt)
SAM.gov registration date
Physical address
1100 Winter St, Waltham, MA 02451, USA
Website
covispharma.com
Founded
2011
Employees
251-1K
Estimated annual revenue
$100M-$250M
Industry
  1. Health Care
  2. Pharmaceuticals, Biotechnology & Life Sciences
  3. Pharmaceuticals
SIC code
28 Chemical & Allied Products
Profiles

Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .

Contract vehicles

Contract awards

Similar vendors

About the company

Amag Pharmaceuticals, Inc. is a global specialty pharmaceutical company that markets therapeutic solutions for patients with life-threatening conditions and chronic illnesses. The company has been registered in the System for Award Management (SAM.gov) since 2009 as a corporate entity classified as a foreign-owned, for-profit manufacturer of goods.

Through prime federal contract awards, Amag Pharmaceuticals, Inc. has supplied the drug bremelanotide, marketed as Vyleesi, to the Department of Veterans Affairs (VA). Vyleesi is a prescription medication used to treat hypoactive sexual desire disorder in premenopausal women. In 2020, the VA Veterans Health Administration Veterans Integrated Service Network 20 awarded a $633 firm-fixed-price delivery order to Amag for Vyleesi against the Pharmaceuticals and Drugs GSA Schedule 61-IB master contract, with performance taking place in Waltham, Massachusetts by June 2021. No set-aside was used for this order.

Amag Pharmaceuticals, Inc. also holds two contract IDVs with the VA for the procurement of Vyleesi. The first is a single-award Blanket Purchase Agreement (BPA) awarded by the VA National Acquisition Center in May 2020 with a potential value of $2.25 million through July 2021, also utilizing the Pharmaceuticals and Drugs GSA Schedule with no set-aside. The BPA facilitates the delivery of Vyleesi to the VA over a five-year term, including an initial base year and four option years. The second IDV is a multiple-award Federal Supply Schedule contract awarded by the VA Veterans Health Administration Veterans Integrated Service Network 12 in September 2019, with a potential value of $111,172,590 through August 2024. This master schedule, FSS-61-IB, enables orders for Vyleesi and other pharmaceuticals and drugs from Amag, as evidenced by the $633 delivery order from VISN 20. These contract vehicles allow the VA to efficiently procure FDA-approved treatment options like Vyleesi for qualifying patients through its nationwide healthcare network while maintaining compliance with federal acquisition regulations.

Quick answers

Is Amag Pharmaceuticals, Inc. registered in SAM.gov?

Amag Pharmaceuticals, Inc.'s SAM.gov registration expired on April 29, 2026.

Which contract vehicles does Amag Pharmaceuticals, Inc. hold?

Amag Pharmaceuticals, Inc. holds a place on 1 federal contract vehicle: FSS-61-IB.

What is Amag Pharmaceuticals, Inc.'s most recent federal award?

Amag Pharmaceuticals, Inc.'s most recent federal contract award is Bremelanotide (vyleesi) (36C26021F0070), from Veterans Integrated Service Network 20 (VHA), on October 30, 2020.

On GovTribe

See Amag Pharmaceuticals, Inc.'s full federal record

  • Federal contract awards
  • IDV awards
  • Contract vehicles
  • Funding analysis by agency, NAICS and set-aside
  • Similar vendors